• November 24, 2020

Leo Lens Pharma Achieves Two Significant Milestones – FDA IND Submission and Seed Round Fundraising Success - Odessa American: Business

e-Edition Subscribe

Leo Lens Pharma Achieves Two Significant Milestones – FDA IND Submission and Seed Round Fundraising Success

Print
Font Size:
Default font size
Larger font size

Posted: Thursday, November 12, 2020 7:51 am | Updated: 8:15 am, Thu Nov 12, 2020.

SAN DIEGO--(BUSINESS WIRE)--Nov 12, 2020--

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, announces the achievement of two significant milestones. The first is the filing in the United States of the Food and Drug Administration's (FDA’s) Investigational New Drug (IND) application for its lead asset, a proprietary drug-eluting, comfort-enhancing contact lens to treat patients suffering from primary open-angle glaucoma or ocular hypertension. The second is the securement of a lead investor, the venture arm of a leading global ophthalmic pharmaceutical company, and initial funding in its Seed round fundraising efforts.

The U.S. FDA’s IND program charts the path by which a pharmaceutical company such as Leo Lens Pharma obtains permission to start human clinical trials before a marketing application for the drug has been approved. The Company’s IND submission is a key step toward being able to start its first human clinical trial with its lead asset, LL-BMT1, to treat primary open-angle glaucoma and ocular hypertension. Current plans are for the first patients in this Phase 2a clinical trial to be enrolled in the coming months.

The strategic lead investor in the Seed round fueled an initial close of the round that exceeded $3 million with $1.5 million coming from new investors. There will be a subsequent close of this round, likely before year-end, when the round is fully or over-subscribed. The funds raised in this round are targeted primarily to support the Phase 2a clinical study along with the end of Phase 2 meeting with the FDA.

“We are enthused to have executed against two pivotal goals that poise Leo Lens Pharma to continue to move forward successfully,” said Dan Myers, CEO of Leo Lens Pharma. “The IND submission step, which gets us closer to beginning our first in-human clinical study, is monumental. We are also excited that our Seed round strategic lead investor has placed their belief in us after significant due diligence to continue to advance our efforts to help glaucoma and ocular hypertension patients protect their sight. We are encouraged too by the excitement from other investors interested in the remaining portion of the round,” he elaborated.

About Leo Lens Pharma

Leo Lens Pharma (Leo Lens) is an emerging San Diego-based pharmaceutical company focused on helping protect sight by developing and commercializing a proprietary continuous ocular drug delivery portfolio. The Company is currently advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye, allergy, and other anterior segment conditions. Using its proprietary MediPrint™ process, Leo Lens will initially commercialize a drug-eluting, comfort-enhancing contact lens to treat millions of glaucoma patients worldwide. While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. This leads millions to suffer from disease progression and thousands to suffer from preventable blindness. There is a large unmet need for a better non-invasive treatment option in this $4B U.S. market. Leo Lens’ patented MediPrint™ process offers a unique value proposition for patients, practitioners, strategic partners, and payers.

For more information please visit www.leolens.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20201112005650/en/

CONTACT: Company Contact:

Kenny Key

Leo Lens Pharma

858-522-0815

kkey@leolens.comMedia Contact:

Orlando Rodrigues

COR Communications

760-212-5727

orodrigues@leolens.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: GENERAL HEALTH HEALTH OPTICAL

SOURCE: Leo Lens Pharma

Copyright Business Wire 2020.

PUB: 11/12/2020 08:51 AM/DISC: 11/12/2020 08:51 AM

http://www.businesswire.com/news/home/20201112005650/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Sunny/Wind
72°
Humidity: 27%
Winds: WSW at 20mph
Feels Like: 72°

Your Extended Forecast

Tomorrow

weather
High 75°/Low 36°
Windy with a few clouds. Highs in the mid 70s and lows in the mid 30s.

wednesday

weather
High 67°/Low 45°
Abundant sunshine. Highs in the upper 60s and lows in the mid 40s.

thursday

weather
High 76°/Low 40°
Mainly sunny. Highs in the mid 70s and lows in the low 40s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7314 to sign up today.